---
input_text: 'Immune responses to AAV in a phase I study for Canavan disease. BACKGROUND:
  Canavan disease is a rare leukodystrophy with no current treatment. rAAV-ASPA has
  been developed for gene delivery to the central nervous system (CNS) for Canavan
  disease. This study represents the first use of a viral vector in an attempt to
  ameliorate a neurodegenerative disorder. METHODS: Subjects received intracranial
  infusions via six cranial burr holes. Adeno-associated virus, serotype 2 (AAV2),
  mediated intraparenchymal delivery of the human aspartoacylase cDNA at a maximum
  dose of 1 x 10(12) vector genomes per subject. The immune response and safety profiles
  were monitored in the follow-up of ten subjects. RESULTS: Following rAAV2 administration,
  we found no evidence of AAV2 neutralizing antibody titers in serum for the majority
  of subjects tested (7/10). In a subset (3/10) of subjects, low to moderately high
  levels of AAV2 neutralizing antibody with respect to baseline were detected. In
  all subjects, there were minimal systemic signs of inflammation or immune stimulation.
  In subjects with catheter access to the brain lateral ventricle, cerebrospinal fluid
  was examined and there was a complete absence of neutralizing antibody titers with
  no overt signs of brain inflammation. CONCLUSIONS: rAAV2 vector administration to
  the human CNS appears well tolerated. The low levels of immune response to AAV2
  detected in 3/10 subjects in this study suggest at this dose and with intraparenchymal
  administration this approach is relatively safe. Long-term monitoring of subjects
  and expansion to phase II/III will be necessary in order to make definitive statements
  on safety and efficacy.'
raw_completion_output: |-
  primary_disease: Canavan disease

  medical_actions: Intracranial infusions; Gene delivery; Monitoring immune response and safety profiles

  symptoms: Signs of inflammation; Immune stimulation; Brain inflammation

  chemicals: rAAV-ASPA; AAV2; Human aspartoacylase cDNA

  action_annotation_relationships: Gene delivery (with rAAV-ASPA) PREVENTS Signs of inflammation IN Canavan disease; Intracranial infusions TREATS Canavan disease; Monitoring immune response and safety profiles PREVENTS Immune stimulation IN Canavan disease; Monitoring immune response and safety profiles PREVENTS Brain inflammation IN Canavan disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Monitoring immune response and safety profiles PREVENTS Brain inflammation IN Canavan disease

  ===

extracted_object:
  primary_disease: MONDO:0010079
  medical_actions:
    - Intracranial infusions
    - Gene delivery
    - Monitoring immune response and safety profiles
  symptoms:
    - Signs of inflammation
    - Immune stimulation
    - HP:0002383
  chemicals:
    - rAAV-ASPA
    - AAV2
    - Human aspartoacylase cDNA
  action_annotation_relationships:
    - subject: Gene delivery
      predicate: PREVENTS
      object: Signs of inflammation
      qualifier: MONDO:0010079
      subject_qualifier: with rAAV-ASPA
      subject_extension: rAAV-ASPA
    - subject: Intracranial infusions
      predicate: TREATS
      object: Canavan disease
    - subject: Monitoring immune response and safety profiles
      predicate: PREVENTS
      object: Immune stimulation
      qualifier: MONDO:0010079
    - subject: Monitoring immune response and safety profiles
      predicate: PREVENTS
      object: HP:0002383
      qualifier: MONDO:0010079
named_entities:
  - id: MONDO:0010079
    label: Canavan disease
  - id: MONDO:0003847
    label: Genetic disorders
  - id: HP:0000739
    label: Anxiety
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:16953
    label: N-acetyl-L-aspartate
  - id: CHEBI:76720
    label: antisense oligonucleotide
  - id: MONDO:0019052
    label: Inborn errors of metabolism (IEM)
  - id: CHEBI:35584
    label: Purines
  - id: CHEBI:16898
    label: Pyrimidines
  - id: CHEBI:35692
    label: Dicarboxylic acids
  - id: CHEBI:16040
    label: Cytosine
  - id: CHEBI:17562
    label: Cytidine
  - id: CHEBI:16737
    label: Creatinine
  - id: CHEBI:17568
    label: Uracil
  - id: CHEBI:16704
    label: Uridine
  - id: CHEBI:17802
    label: Beta-pseudouridine
  - id: CHEBI:16708
    label: Adenine
  - id: CHEBI:38635
    label: 3-methyladenine
  - id: CHEBI:17368
    label: Hypoxanthine
  - id: CHEBI:15318
    label: Xanthine
  - id: CHEBI:18107
    label: Xanthosine
  - id: CHEBI:17596
    label: Inosine
  - id: CHEBI:16750
    label: Guanosine
  - id: CHEBI:22652
    label: Ascorbic acid
  - id: CHEBI:17821
    label: Thymine
  - id: CHEBI:17748
    label: Thymidine
  - id: CHEBI:27226
    label: Uric acid
  - id: CHEBI:68441
    label: 1-methyluric acid
  - id: CHEBI:16742
    label: Orotic acid
  - id: CHEBI:76931
    label: N-acetylaspartylglutamate
  - id: CHEBI:30794
    label: Malonic acid
  - id: CHEBI:30860
    label: Methylmalonic acid
  - id: CHEBI:16856
    label: GSH
  - id: CHEBI:17858
    label: GSSG
  - id: CHEBI:30145
    label: lithium
  - id: MONDO:0019046
    label: leukodystrophies
  - id: MAXO:0000127
    label: genetic testing
  - id: MAXO:0009004
    label: whole exome sequencing (WES)
  - id: MAXO:0000079
    label: genetic counseling
  - id: HP:0000256
    label: Macrocephaly
  - id: HP:0001249
    label: Mental retardation
  - id: HP:0001252
    label: Hypotonia
  - id: CHEBI:21547
    label: N-acetylaspartic acid
  - id: CHEBI:27881
    label: Resveratrol (RSV)
  - id: HP:0001355
    label: Megalencephaly
  - id: HP:0001263
    label: Developmental delay
  - id: MAXO:0000068
    label: Transplantation
  - id: MONDO:0011925
    label: merosin-negative congenital muscular dystrophy
  - id: MAXO:0000387
    label: muscle biopsy
  - id: HP:0002350
    label: cerebellar cysts
  - id: CHEBI:33375
    label: gadolinium
  - id: HP:0001250
    label: Seizures
  - id: HP:0000750
    label: Speech delay
  - id: CHEBI:15354
    label: Choline
  - id: MONDO:0019262
    label: Batten disease
  - id: MONDO:0005180
    label: Parkinson's disease
  - id: MONDO:0008752
    label: Alexander disease
  - id: MONDO:0011380
    label: CACH/VWM
  - id: HP:0003819
    label: death in childhood
  - id: HP:0000407
    label: sensorineural hearing loss
  - id: MONDO:0010100
    label: Tay-Sachs disease
  - id: MONDO:0008876
    label: Bloom syndrome
  - id: MONDO:0009061
    label: cystic fibrosis
  - id: MONDO:0009131
    label: familial dysautonomia
  - id: MONDO:0009653
    label: mucolipidosis type IV
  - id: HP:0010864
    label: severe mental retardation
  - id: CHEBI:73688
    label: N-acetylaspartylglutamic acid
  - id: HP:0002415
    label: Leukodystrophies
  - id: HP:0003269
    label: Pelizaeus-Merzbacher disease
  - id: MONDO:0005648
    label: Autosomal recessive (AR) conditions; Autosomal dominant (AD) conditions;
      X-linked (XL) conditions
  - id: MAXO:0000530
    label: Genetic carrier screening
  - id: MONDO:0005071
    label: neurologic disease
  - id: CHEBI:9661
    label: Glyceryl triacetate
  - id: CHEBI:30089
    label: Acetate
  - id: CHEBI:22660
    label: Aspartic acid
  - id: MAXO:0009003
    label: preimplantation genetic diagnosis (PGD)
  - id: CHEBI:15366
    label: Acetic acid
  - id: CHEBI:18237
    label: Glutamic acid
  - id: MAXO:0001001
    label: gene therapy
  - id: CHEBI:157802
    label: Creatine (Cr)
  - id: CHEBI:53620
    label: Myo-Inositol (mI)
  - id: CHEBI:24996
    label: Lactate
  - id: CHEBI:16813
    label: Galactitol
  - id: CHEBI:22918
    label: Branched chain amino acids
  - id: MONDO:0018660
    label: Hemophilia
  - id: MONDO:0013282
    label: Alpha-1-antitrypsin Deficiency
  - id: CHEBI:17053
    label: l-aspartic acid
  - id: HP:0000952
    label: Jaundice
  - id: HP:0001942
    label: Metabolic acidosis
  - id: HP:0012734
    label: Ketotic hypoglycemia
  - id: HP:0001987
    label: Hyperammonemia
  - id: CHEBI:132943
    label: Aspartate
  - id: HP:0000618
    label: vision impairment
  - id: HP:0001141
    label: severe vision loss
  - id: HP:0000510
    label: Retinitis pigmentosa
  - id: HP:0032988
    label: Head lag
  - id: HP:0001257
    label: Spasticity
  - id: CHEBI:29987
    label: Glutamate
  - id: CHEBI:16865
    label: GABA
  - id: HP:0001276
    label: Increased muscle tone
  - id: HP:0025464
    label: oxidative stress
  - id: CHEBI:16240
    label: Hydrogen peroxide
  - id: MAXO:0000016
    label: cell therapy
  - id: HP:0012447
    label: Abnormal myelination
  - id: MONDO:0021042
    label: glioma
  - id: CHEBI:45716
    label: Vorinostat (SAHA)
  - id: CHEBI:72564
    label: Temozolomide (TMZ)
  - id: HP:0009733
    label: glioma
  - id: HP:0002383
    label: Brain inflammation
